Given the abundant evidence for immune exhaustion in chronic virus infections and virus-associated malignancies [62, 73], anti-PD-L1 blockers deserve to be investigated as a therapeutic strategy in virus-associated cancers. Here, CD274 is linked to viral infectious disease.